Addex Therapeutics (Switzerland) Analysis

Addex Stock Analysis Notes

The company has price-to-book (P/B) ratio of 1.23. Some equities with similar Price to Book (P/B) outperform the market in the long run. Addex Therapeutics recorded a loss per share of 0.06. The entity last dividend was issued on the 26th of July 2022. Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system disorders in Switzerland. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Plan-les-Ouates, Switzerland. ADDEX N operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 17 people. For more info on Addex Therapeutics please contact Timothy Dyer at 41 22 884 1555 or go to https://www.addextherapeutics.com.

Addex Therapeutics Investment Alerts

Addex Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.39 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Addex Therapeutics's market, we take the total number of its shares issued and multiply it by Addex Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Addex Profitablity

Management Efficiency

Addex Therapeutics has return on total asset (ROA) of (0.159) % which means that it has lost $0.159 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7284) %, meaning that it generated substantial loss on money invested by shareholders. Addex Therapeutics' management efficiency ratios could be used to measure how well Addex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Addex Therapeutics' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to climb to 0.80 in 2026, whereas Return On Capital Employed is likely to drop (0.34) in 2026. At this time, Addex Therapeutics' Non Current Assets Total are fairly stable compared to the past year. Return On Tangible Assets is likely to climb to 0.80 in 2026, whereas Non Currrent Assets Other are likely to drop 6,060 in 2026.

Technical Drivers

As of the 18th of February 2026, Addex Therapeutics shows the mean deviation of 2.68, and Risk Adjusted Performance of (0.05). Addex Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Addex Therapeutics mean deviation, standard deviation, information ratio, as well as the relationship between the coefficient of variation and variance to decide if Addex Therapeutics is priced correctly, providing market reflects its regular price of 0.0486 per share.

Addex Therapeutics Price Movement Analysis

Addex Therapeutics Outstanding Bonds

Addex Therapeutics Predictive Daily Indicators

Addex Therapeutics Forecast Models

Addex Therapeutics' time-series forecasting models are one of many Addex Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Addex Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Addex Therapeutics Debt to Cash Allocation

Addex Therapeutics has accumulated 41.99 K in total debt. Addex Therapeutics has a current ratio of 17.7, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Addex Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Addex Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Addex Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Addex to invest in growth at high rates of return. When we think about Addex Therapeutics' use of debt, we should always consider it together with cash and equity.

Addex Therapeutics Total Assets Over Time

Addex Therapeutics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Addex Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Addex Therapeutics Debt Ratio

0.34

It appears most of the Addex Therapeutics' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Addex Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Addex Therapeutics, which in turn will lower the firm's financial flexibility.

Addex Therapeutics Corporate Bonds Issued

Addex Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Addex Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Addex shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Addex Therapeutics. By using and applying Addex Stock analysis, traders can create a robust methodology for identifying Addex entry and exit points for their positions.

When running Addex Therapeutics' price analysis, check to measure Addex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Addex Therapeutics is operating at the current time. Most of Addex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Addex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Addex Therapeutics' price. Additionally, you may evaluate how the addition of Addex Therapeutics to your portfolios can decrease your overall portfolio volatility.